Skip to content
OpenCapital
Get started

Madrigal Pharmaceuticals, Inc. MDGL Proceeds From Sale And Maturity Of Available For Sale Securities

Proceeds From Sale And Maturity Of Available For Sale Securities at other companies

Atlassian logo
AtlassianTEAM
$352.09M+17,522%
Arch Capital Group logo
Arch Capital GroupACGL
$224.42M-17.9%
Principal Financial Group logo
Principal Financial GroupPFG
$940.5M-38.6%
Clean Harbors logo
Clean HarborsCLH
$3.26M+1,243%
Wintrust Financial logo
Wintrust FinancialWTFC
$204.36M+51.2%
Elevance Health logo
Elevance HealthELV
$3.09B-25.4%

Other financials

Income statement

See full
Revenue$311.3M+127%
Gross profit$43.5M—
Operating income-$92.7M-16.9%
Net income-$94.4M-28.9%
EPS (diluted)-$3.25-24.5%

Balance sheet

See full
Cash & equivalents$232.2M+23.1%
Total debt$377.3M+187%
Total equity$543.5M-23.5%
Total assets$1.2B+23.1%

Cash flow

See full
Operating cash flow-$167.4M-88.4%
CapEx$3.8M—
Free cash flow-$171.3M-92.7%

Valuation

See full
Market cap$11.66B+64.2%
Enterprise value$11.81B+67.5%
P/S10.3×-12.1×

Profitability

See full
Gross margin96.5%—
Operating margin-27.7%-12.2pp
Net margin-27.3%-12.0pp
FCF margin-59.8%-29.6pp

Returns & leverage

See full
Return on equity-49.3%-0.8pp
Debt / equity0.7×+0.5×
Current ratio3.5×-2.4×

Where this comes from

Reported directly by Madrigal Pharmaceuticals, Inc. in its filing.

Tagged under the XBRL concept us-gaap:ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities.

The official record: Madrigal Pharmaceuticals, Inc.’s 10-Q, filed May 6, 2026, on SEC EDGAR. View the filing →

Ask your AI about Madrigal Pharmaceuticals, Inc.'s proceeds from sale and maturity of available for sale securities.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Madrigal Pharmaceuticals, Inc.'s proceeds from sale and maturity of available for sale securities?
Madrigal Pharmaceuticals, Inc. (MDGL) reported proceeds from sale and maturity of available for sale securities of $353.87M in Q1 2026.
How has Madrigal Pharmaceuticals, Inc.'s proceeds from sale and maturity of available for sale securities changed year-over-year?
Madrigal Pharmaceuticals, Inc.'s proceeds from sale and maturity of available for sale securities increased by 20.1% year-over-year, from $294.69M to $353.87M.
What is the long-term trend for Madrigal Pharmaceuticals, Inc.'s proceeds from sale and maturity of available for sale securities?
Over 4 years (2021 to 2025), Madrigal Pharmaceuticals, Inc.'s proceeds from sale and maturity of available for sale securities has grown at a 29.2% compound annual growth rate (CAGR), from $389.27M to $1.08B.